# Diet, nutrition, and hormone therapy for prostate cancer: a systematic review with implications for future interventions

**Authors:** Isabella Pahulu, Matthew Calumpit, Paul Tominez, Jonathan J Shih, Sasha Ebrahimi, Nicole V Deville, Raynald Samoa, Tannaz Moin, Mina S Sedrak, Luca F Valle, Michael Steinberg, Amar U Kishan, Patricia A Ganz, Kekoa Taparra

PMC · DOI: 10.1093/jncics/pkag014 · JNCI Cancer Spectrum · 2026-02-17

## TL;DR

This review explores how diet and weight management can help reduce the negative effects of hormone therapy in prostate cancer patients.

## Contribution

The study provides a systematic review of recent RCTs on diet and ADT, highlighting safe and feasible nutritional interventions.

## Key findings

- Mediterranean and low-carbohydrate diets with exercise reduced cardiovascular and metabolic risk factors.
- Creatine showed a trend toward increasing lean muscle mass in patients.
- Multidisciplinary care improved outcome durability and patient accountability.

## Abstract

Given excellent prostate cancer outcomes, comorbidity management is critical to survivorship. While hormone therapy or androgen deprivation therapy (ADT) is a mainstay of treatment, they can negatively impact quality of life and survivorship through cardiovascular, sexual, and metabolic effects. ADT-induced metabolic syndrome causes impaired glucose tolerance, muscle mass loss, and weight gain. This systematic review examined recent randomized clinical trials (RCTs) investigating the impact of diet and weight management strategies on mitigating ADT-related adverse effects.

A systematic review of RCTs (2015-2025) was performed using PubMed/Embase following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. To identify how diet and weight management impacts ADT symptoms, search terms included: “prostate cancer,” “diet,” “nutrition,” “glucagon-like peptide-1 receptor agonists” (GLP-1RA), and “ADT.” Risk of Bias 2 (ROB2) and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tools evaluated RCT quality.

Of 2799 publications, 16 met inclusion/exclusion criteria (range, 23-96 patients/RCT). No RCTs had a high risk of bias or evaluated GLP-1RA. Outcomes included metabolic labs, body composition, and quality of life. Mediterranean and low-carbohydrate diets with exercise reduced cardiovascular and metabolic risk factors, with variable durability. Creatine trended toward increasing lean muscle mass. Multidisciplinary care and community involvement improved accountability and outcome durability.

This comprehensive review of diet and ADT in prostate cancer identified nutritional interventions that were safe, feasible, and may be recommended as part of prostate cancer treatment and survivorship. Future RCTs should evaluate optimal diet duration, longer follow-up, multidisciplinary patient support, and novel anti-metabolic therapies like GLP-1RA.

## Linked entities

- **Diseases:** prostate cancer (MONDO:0005159), metabolic syndrome (MONDO:0000816)

## Full-text entities

- **Genes:** PLAG1 (PLAG1 zinc finger) [NCBI Gene 5324] {aka PSA, SGPA, SRS4, ZNF912}, AR (androgen receptor) [NCBI Gene 367] {aka AIS, AR8, DHTR, HPCX3, HUMARA, HYSP1}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}
- **Diseases:** Metabolic dysregulation (MESH:D021081), muscle mass loss (MESH:C536030), vasomotor (MESH:D012223), obesity (MESH:D009765), weight gain (MESH:D015430), bone mineral density loss (MESH:D001851), Fatigue (MESH:D005221), sexual dysfunction (MESH:D012735), Diabetes (MESH:D003920), Cancer (MESH:D009369), sexual bother (MESH:D050035), urinary irritation (MESH:D001523), Prostate Cancer (MESH:D011471), Metabolic Syndrome (MESH:D024821), hyperglycemia (MESH:D006943), inflammatory (MESH:D007249), sarcopenia (MESH:D055948), headaches (MESH:D006261), Hot Flash (MESH:D019584), coronary heart disease (MESH:D003327), fractures (MESH:D050723), dyslipidemia (MESH:D050171), impaired glucose tolerance (MESH:D018149), Chronic Illness (MESH:D002908), ADT (MESH:D014770), breast and prostate cancer (MESH:D001943), T2DM (MESH:D003924), GI and musculoskeletal (MESH:D009140), loss of lean muscle (MESH:D013851), non-cutaneous malignancy (MESH:C562393), dementia (MESH:D003704), constipation (MESH:D003248), male cancers (MESH:D018567), urinary obstructive symptoms (MESH:D059411), infection (MESH:D007239), osteoporosis (MESH:D010024), Insulin Resistance (MESH:D007333), Bone (MESH:D001847), weight (MESH:D015431), toxicities (MESH:D064420), Symptom (MESH:D012816), bone metastases (MESH:D009362)
- **Chemicals:** blood sugar (MESH:D001786), Cholesterol (MESH:D002784), metformin (MESH:D008687), exenatide (MESH:D000077270), triglycerides (MESH:D014280), vitamin D (MESH:D014807), bicalutamide (MESH:C053541), Fat (MESH:D005223), salt (MESH:D012492), alcohol (MESH:D000438), calcium (MESH:D002118), creatinine (MESH:D003404), Glucose (MESH:D005947), darolutamide (MESH:C000607739), enzalutamide (MESH:C540278), lipid (MESH:D008055), Creatine (MESH:D003401), apalutamide (MESH:C572045), Carbohydrate (MESH:D002241), ADT (-)
- **Species:** Homo sapiens (human, species) [taxon 9606], Solanum lycopersicum (tomato, species) [taxon 4081]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12972670/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12972670/full.md

## References

65 references — full list in the complete paper: https://tomesphere.com/paper/PMC12972670/full.md

---
Source: https://tomesphere.com/paper/PMC12972670